var data={"title":"Tolvaptan: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tolvaptan: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/385790?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tolvaptan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tolvaptan: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810723\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Treatment initiation and monitoring: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Initiate and reinitiate tolvaptan in patients only in a hospital where serum sodium can be closely monitored.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Too rapid correction of hyponatremia (eg, more than 12 mEq/L per 24 hours) can cause osmotic demyelination, resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and/or death. In susceptible patients, including those with severe malnutrition, alcoholism, or advanced liver disease, slower rates of correction may be advisable.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7794510\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Samsca</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13276923\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Jinarc;</li>\n      <li>Samsca</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810547\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vasopressin Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810606\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyponatremia:</b> Oral: Samsca: Initial: 15 mg once daily; after at least 24 hours, may increase to 30 mg once daily to a maximum of 60 mg once daily titrating at 24-hour intervals to desired serum sodium concentration. Avoid fluid restriction during the first 24 hours of therapy. Do not use for more than 30 days due to the risk of hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Autosomal dominant polycystic kidney disease (ADPKD):</b> Jinarc [Canadian product]: Oral: <b>Note: </b>Prior to initiating therapy, restrict overnight fluid intake for 10 to 14 hours to assess ability to concentrate urine using urine osmolality or specific gravity (less accurate). Upon initiation of therapy fluid intake should not be restricted.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 60 mg/day in divided doses (45 mg upon wakening and 15 mg approximately 8 hours later); titrate per response and tolerability at intervals of at least 7 days to 90 mg/day (60 mg upon wakening and 30 mg approximately 8 hours later) and then to 120 mg/day (90 mg upon wakening and 30 mg approximately 8 hours later). Downward titration may be necessary based on tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Maintain patient on highest tolerated dose to decrease urine osmolality 200 to 300 mOsm/kg (preferable in most cases) from baseline. Urine osmolality or specific gravity should be measured before morning dose. Urine osmolality &lt;300 mOsm/kg (corresponds to a specific gravity of 1.005) should be maintained at all times if possible. Avoid unnecessary interruptions in therapy; however if the ability to drink or accessibility to water is limited therapy should be interrupted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment with concomitant medication:</b> Jinarc [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Strong CYP3A inhibitors (eg, ketoconazole, clarithromycin, ritonavir, saquinavir): Patients receiving tolvaptan 120 mg/day or 90 mg/day: Reduce dose to 30 mg/day administered upon wakening. Patients receiving tolvaptan 60 mg/day: Reduce dose to 15 mg/day administered upon wakening. Titrate cautiously per response and tolerability. Further downward titration or discontinuation of concurrent therapy may be necessary based on tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate CYP3A inhibitors (eg, erythromycin, fluconazole, verapamil): Decrease daily dose by 50% administered as split regimen with first dose upon wakening and second dose ~8 hours later (eg, 120 mg/day [90 mg + 30 mg/day] is reduced to 60 mg/day [45 mg + 15 mg/day]). When adjusting the dose reduce the first daily dose as needed and maintain the second daily dose at 15 mg.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810607\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13797229\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;10 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;10 mL/minute: Use not recommended (has not been studied); contraindicated in anuria (no benefit expected).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13797228\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Samsca: Avoid use in patients with underlying liver disease, including cirrhosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Jinarc [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preexisting hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution and monitor closely. Avoid initiation of therapy if AST/ALT &gt;3 times ULN. Use is contraindicated in patients with clinically relevant impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosage adjustment for toxicity (during therapy): Interrupt therapy if hepatotoxicity is suspected and promptly evaluate hepatic function; upon resolution may consider reinitiating therapy cautiously.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT or AST &lt;3 times ULN: Continue therapy cautiously and monitor frequently.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Permanently discontinue for any the following: ALT or AST &gt;8 times ULN, ALT or AST &gt;5 times ULN for &gt;2 weeks, ALT or AST &gt;3 times ULN and total bilirubin &gt;2 times ULN or INR &gt;1.5, ALT or AST &gt;3 times ULN with persistent symptoms of hepatic injury.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810612\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Samsca: 15 mg, 30 mg [contains fd&amp;c blue #2 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810545\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13276924\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Jinarc: 15 mg, 30 mg, 45 mg, 60 mg, 90 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Samsca: 60 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28839188\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Jinarc [Canadian product]: Only physicians experienced in the diagnosis and treatment of polycystic kidney disease should prescribe Jinarc. Prior to initiating therapy, a patient-prescriber agreement (PPAF) is required outlining relevant patient selection criteria for consideration, expected benefits and risks of treatment, and the need for mandatory hepatic function monitoring. Jinarc is available only through a hepatic safety monitoring and distribution program conducted and maintained by Otsuka Canada Pharmaceuticals Incorporated. All patients initiating therapy should be offered participation in the Canadian Jinarc patient outcomes registry.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11213964\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM235540.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68A1YhthLkJzYfc+blova5hg==&amp;TOPIC_ID=9512\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM235540.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810608\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Samsca: Oral: Treatment should be initiated or reinitiated in a hospital. May be administered without regards to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasogastric (NG) tube: Administration via NG tube resulted in an ~25% reduction in AUC and a modest reduction in C<sub>max</sub> in one study; 24-hour urine output was reduced by only 2.8%. Therefore, until further studies are done to determine a bioequivalent dose when administering via NG tube, NG tube administration of a crushed 15 mg tablet appears to be a viable alternative method of administration (McNeely, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Jinarc [Canadian product]: Oral: May be administered without regards to meals. Interrupt therapy if the ability to drink or accessibility to water is limited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810548\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Samsca:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypervolemic and euvolemic hyponatremia:</b> Treatment of clinically significant hypervolemic or euvolemic hyponatremia (serum sodium &lt;125 mEq/L or less marked hyponatremia that is symptomatic and resistant to fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Not indicated for use when urgent treatment of hyponatremia is required to prevent or treat serious neurological symptoms. It has not been established that raising serum sodium with tolvaptan provides symptomatic benefit.</p>\n    <p style=\"text-indent:0em;\">\n      <b>Jinarc [Canadian product]:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Autosomal dominant polycystic kidney disease (ADPKD):</b> Slow the progression of kidney enlargement in patients with ADPKD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Clinical trials evaluated ADPKD patients having a total kidney volume &ge;750 mL with relatively preserved renal function (eg, estimated creatinine clearance &ge;60 mL/minute, generally corresponding to a CKD-EPI eGFR &ge;30 mL/minute/1.73 m<sup>2</sup> at the time of therapy initiation).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810563\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased thirst (12% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (21%), xerostomia (7% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Polyuria (including pollakiuria, 4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">2% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (6%), hypernatremia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal hemorrhage (cirrhosis patients 10%), constipation (7%), anorexia (4%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatotoxicity (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;2%, postmarketing, and/or case reports: Anaphylactic shock, cerebrovascular accident, deep vein thrombosis, diabetic ketoacidosis, disseminated intravascular coagulation, hypersensitivity reaction, increased serum ALT, increased serum bilirubin, intracardiac thrombus, ischemic colitis, osmotic demyelination syndrome, prolonged prothrombin time, pulmonary embolism, respiratory failure, rhabdomyolysis, skin rash, urethral bleeding, vaginal hemorrhage, ventricular fibrillation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810553\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Samsca: Hypersensitivity (eg, anaphylactic shock, generalized rash) to tolvaptan or any component of the formulation; hypovolemic hyponatremia; urgent need to raise serum sodium acutely; use in patients unable to sense or appropriately respond to thirst; anuria; concurrent use with strong CYP3A inhibitors (eg, ketoconazole, itraconazole, ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, telithromycin, clarithromycin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Jinarc [Canadian product]: Hypersensitivity to tolvaptan or any component of the formulation; hypovolemia; hypernatremia; use in patients unable to sense or appropriately respond to thirst; clinically relevant hepatic impairment; anuria; pregnancy; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810554\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Dizziness, asthenia, and/or syncope have been reported when used for ADPKD; advise patients to use caution when performing dangerous tasks (eg, driving, operating machinery).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Tolvaptan may increase the risk of serious hepatotoxicity, including fatal hepatotoxicity. Cases of hepatotoxicity have been reported in patients treated for ADPKD and have usually occurred after 3 months of therapy although some cases occurred prior to 3 months. Therefore, treatment with Samsca should be limited to 30 days. If hepatotoxicity is suspected, discontinue use. Avoid use in patients with liver disease (including cirrhosis) since the ability to recover from further liver injury may be impaired. In the treatment of ADPKD, use of Jinarc [Canadian product] is not limited to 30 days however close monitoring of hepatic function is recommended. Interrupt therapy for signs/symptoms of hepatotoxicity (eg, anorexia, dark urine, jaundice, itching, fatigue, nausea, right upper abdominal pain) and evaluate hepatic function promptly (ie, within 48 to 72 hours) then increase the frequency of hepatic function testing; upon resolution may consider cautious reinitiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperuricemia/Gout: Hyperuricemia and gout have been observed; in the treatment of ADPKD, monitoring of serum uric acid is recommended (Jinarc Canadian product monograph, 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypovolemia/dehydration: Patients should ingest fluids in response to thirst during therapy. Interrupt or discontinue therapy in patients who develop significant signs or symptoms of hypovolemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serum sodium monitoring/initiating in hospital: <b>[US Boxed Warning]: Tolvaptan should be initiated and reinitiated in patients only in a hospital where serum sodium can be closely monitored. Too rapid correction of hyponatremia (ie, &gt;12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. In susceptible patients (including those with severe malnutrition, alcoholism, or advanced liver disease), slower rates of correction may be advisable.</b> Patients with SIADH, very low baseline, or patients who are fluid restricted during the first 24 hours of therapy may be at greater risk of overly-rapid correction. Avoid fluid restriction during the initial 24 hours of therapy. Discontinue or interrupt therapy if sodium correction is too rapid and consider administration of hypotonic fluids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Avoid use in patients with liver disease, including those with cirrhosis, since the ability to recover from further liver injury may be impaired. In addition, patients with cirrhosis have a higher risk of gastrointestinal bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Reductions in extracellular fluid volumes may cause hyperkalemia. Patients using concomitant medications that may increase potassium levels or with a pretreatment serum potassium &gt;5 mEq/L should be monitored after initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use in patients with creatinine clearance &lt;10 mL/minute is not recommended; has not been studied. Use is contraindicated in patients who are anuric.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Monitor closely for rate of serum sodium increase and neurological status; rapid serum sodium correction (&gt;12 mEq/L/24 hours) can lead to permanent neurological damage. Discontinue use if rate of serum sodium increase is undesirable; fluid restriction during the first 24 hours of sodium correction can increase the risk of overly-rapid correction and should generally be avoided; not intended for urgent correction of serum sodium to prevent or treat serious neurologic symptoms; it has not been demonstrated that raising serum sodium with tolvaptan provides a symptomatic benefit. . In the treatment of ADPKD, patients most likely to benefit from therapy are those with rapidly progressive disease or those who are developing progressive disease but lack extensive renal damage. Factors associated with rapid progression include large total renal cyst mass for a given age (measured by total kidney volume), chronic kidney disease stage 2 to 3, rapid deterioration of renal function, systemic hypertension or albuminuria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Limitations of use: SIADH: Limitations to the use of tolvaptan in SIADH may exist due to concerns about safety, such as overly rapid correction of hyponatremia and potential for hepatotoxicity (Spasovski, 2014). Based on available evidence, European clinical practice guidelines recommend against the use of vasopressin receptor antagonists in the treatment of hyponatremia in patients with SIADH (Spasovski, 2014). Additional data may be necessary to define the appropriate clinical role of tolvaptan in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9838565\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7832267\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9512&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Tolvaptan may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Tolvaptan may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Tolvaptan. Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Tolvaptan.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tolvaptan.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Tolvaptan may diminish the therapeutic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Tolvaptan may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Tolvaptan may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Chloride: May enhance the adverse/toxic effect of Tolvaptan. Specifically, Hypertonic Saline may increase the risk for too rapid of an increase in serum sodium concentrations. Management: This interaction is specific to Hypertonic Saline.  Avoid concurrent use of Hypertonic Saline with Tolvaptan.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Tolvaptan. Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810568\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Tolvaptan exposure may be doubled when taken with grapefruit juice. Management: Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810549\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810550\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17917968\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if tolvaptan is excreted in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810581\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase tolvaptan serum concentrations. Management: Avoid concurrent use with grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810610\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum sodium concentration, rate of serum sodium increase, serum potassium concentration (if &gt;5 mEq/L prior to administration or receiving medications known to elevate serum potassium); volume status; hepatic function and/or signs of drug induced hepatotoxicity (eg, anorexia, fatigue, right upper abdominal discomfort, jaundice, dark urine, itching) as indicated.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Additional monitoring recommendations: Jinarc [Canadian product]: Hepatic function testing prior to therapy initiation, monthly for the first 18 months, then every 3 months for 12 months, and then every 3 to 6 months during therapy. If signs/symptoms of hepatotoxicity, obtain ALT/AST, total bilirubin, alkaline phosphatase promptly (ie, within 48 to 72 hours) and increase frequency of testing until clinical/laboratory signs of resolution; urine osmolality or specific gravity (trough level prior to morning dose); serum uric acid (prior to initiation and as indicated during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810582\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">An arginine vasopressin (AVP) receptor antagonist with affinity for AVP receptor subtypes V<sub>2</sub> and V<sub>1a</sub> in a ratio of 29:1. Antagonism of the V<sub>2</sub> receptor by tolvaptan promotes the excretion of free water (without loss of serum electrolytes) resulting in net fluid loss, increased urine output, decreased urine osmolality, and subsequent restoration of normal serum sodium levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7810571\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: 4 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 60% peak serum sodium elevation is retained at 24 hours; urinary excretion of free water is no longer elevated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~12 hours; dominant half-life &lt;12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (19% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321967\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Samsca Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (10): $5,151.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (10): $5,344.56</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390224\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Jinarc (GB, HK, IE);</li>\n      <li>Natrise (IN);</li>\n      <li>Samsca (AT, AU, BB, CZ, DE, DK, EE, ES, FR, GB, HK, HR, HU, ID, IE, JP, KR, LT, MT, NL, NO, PH, PL, PT, RO, SE, SK, TH, VN);</li>\n      <li>Tolvat (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ali F, Guglin M, Vaitkevicus P, et al, &ldquo;Therapeutic Potential of Vasopressin Receptor Antagonists,&rdquo; <i>Drugs</i>, 2007, 67(6):847-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tolvaptan-drug-information/abstract-text/17428103/pubmed\" target=\"_blank\" id=\"17428103\">17428103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Decaux G, Soupart A, Vassart G, &ldquo;Non-Peptide Arginine-Vasopressin Antagonists: The Vaptans,&rdquo; <i>Lancet</i>, 2008, 371(9624):1624-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tolvaptan-drug-information/abstract-text/18468546/pubmed\" target=\"_blank\" id=\"18468546\">18468546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gheorghiade M, Konstam MA, Burnett JC Jr, &ldquo;Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure,&rdquo; <i>JAMA</i>, 2007, 297(12):1332-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tolvaptan-drug-information/abstract-text/17384438/pubmed\" target=\"_blank\" id=\"17384438\">17384438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jinarc (tolvaptan) [product monograph]. Saint-Laurent, Quebec, Canada: Otsuka Canada Pharmaceuticals Inc; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konstam MA, Gheorghiade M, Burnett JC Jr, et al, &ldquo;Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial,&rdquo; <i>JAMA</i>, 2007, 297(12):1319-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tolvaptan-drug-information/abstract-text/17384437/pubmed\" target=\"_blank\" id=\"17384437\">17384437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McNeely EB, Hull JH, Adams KF, et al, &ldquo;Comparison of the Relative Oral Bioavailability of Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact,&rdquo; 2012, 25 (abstract 25 ACCP)</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oghlakian G and Klapholz M, &ldquo;Vasopressin and Vasopressin Receptor Antagonists in Heart Failure,&rdquo; <i>Cardiol Rev</i>, 2009, 17(1):10-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tolvaptan-drug-information/abstract-text/19092365/pubmed\" target=\"_blank\" id=\"19092365\">19092365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samsca (tolvaptan) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samsca (tolvaptan) [product monograph]. Otsuka Canada Pharmaceuticals Inc; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shoaf SE, Bramer SL, Bricmont P, et al, &ldquo;Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan, a Non-peptide AVP Antagonist, and Furosemide or Hydrochlorothiazide,&rdquo; <i>J Cardiovasc Pharmacol</i>, 2007, 50(2):213-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tolvaptan-drug-information/abstract-text/17703139/pubmed\" target=\"_blank\" id=\"17703139\">17703139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shoaf SE, Elizari MV, Wang Z, et al, &ldquo;Tolvaptan Administration Does Not Affect Steady State Amiodarone Concentrations in Patients With Cardiac Arrhythmias,&rdquo; <i>J Cardiovasc Pharmacol Ther</i>, 2005, 10(3):165-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tolvaptan-drug-information/abstract-text/16211205/pubmed\" target=\"_blank\" id=\"16211205\">16211205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spasovski G, Vanholder R, Allolio B, et al; Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia [published correction appears in <i>Eur J Endocrinol</i>. 2014;171(1):X1]. <i>Eur J Endocrinol</i>. 2014;170(3):G1-G47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tolvaptan-drug-information/abstract-text/24569125/pubmed\" target=\"_blank\" id=\"24569125\">24569125</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9512 Version 134.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F7810723\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7794510\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13276923\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7810547\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7810606\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7810607\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13797229\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13797228\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F7810612\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F7810545\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F13276924\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F28839188\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11213964\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7810608\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7810548\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7810563\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7810553\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7810554\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9838565\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7832267\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F7810568\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F7810549\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7810550\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17917968\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F7810581\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7810610\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7810582\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7810571\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321967\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390224\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9512|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tolvaptan-patient-drug-information\" class=\"drug drug_patient\">Tolvaptan: Patient drug information</a></li></ul></div></div>","javascript":null}